Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist

Add time:07/13/2019    Source:sciencedirect.com

Structure–activity relationship studies in a series of diarylpyrazolyl thiadiazoles identified cannabinoid-1 receptor antagonists with excellent potency and selectivity. Based on its exceptional in vivo efficacy in animal models and its favorable pharmacokinetic and toxicological profiles, 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) was selected as a preclinical candidate for the treatment of obesity.

We also recommend Trading Suppliers and Manufacturers of 2-[4-(BROMOMETHYL)PHENYL]-5-METHYL-1,3,4-OXADIAZOLE (cas 946409-17-2). Pls Click Website Link as below: cas 946409-17-2 suppliers

Prev:Design, synthesis, and biological evaluation of novel oxadiazole- and thiazole-based histamine H3R ligands
Next:A new “ON-OFF” fluorescent and colorimetric chemosensor based on 1,3,4-oxadiazole derivative for the detection of Cu2+ ions)